Johnson & Johnson stock trades near a 52-week high after Q2 beat
Published on 08/26/2026 at 08:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock (US4781601046) closed at $273.14 on August 25, 2026, after a session that ranged from $270.18 to $273.80 and left the shares just below the 52-week high of $276.47. The market value stood at $658.24 billion, while the stock finished up $1.44, or 0.53%, on the day.
Q2 numbers still matter
The company reported second-quarter revenue of $25.31 billion and adjusted EPS of $2.90 for the period ended June 30, 2026. That revenue rose 6.6% from a year earlier, and EPS beat the $2.84 consensus by $0.06.
Guidance also remained constructive. Johnson & Johnson kept fiscal 2026 EPS guidance at $11.60 to $11.75, while market commentary points to consensus near $11.61 for the full year.
Dividend and valuation
The stock traded ex-dividend on August 25, 2026, for a quarterly payout of $1.34 per share, equal to $5.36 annualized. The implied yield was 1.96% and the forward P/E stood at 22.86, versus a trailing P/E of 31.67.
That mix matters because the stock is already priced close to its high end. The 52-week range sits between $173.33 and $276.47, so the latest close leaves little distance to the top of that band.
What the portfolio leans on
Johnson & Johnson's portfolio still spans Innovative Medicine and MedTech, with products such as DARZALEX, TREMFYA and CARVYKTI carrying much of the recent growth story. On the latest quarterly readout, that breadth helped offset pressure from older franchises and kept sales growth positive.
For investors, the key comparison is simple: $25.31 billion in quarterly sales, $2.90 in adjusted EPS and $11.60 to $11.75 in full-year EPS guidance now sit alongside a market cap of $658.24 billion and a stock price that ended August 25, 2026, near the top of its yearly range.
Market snapshot
Company: Johnson & Johnson Inc.
ISIN: US4781601046
Ticker: JNJ
Exchange: NYSE
Price (as of August 25, 2026, 4:00 p.m. ET): $273.14 USD
Market cap: $658.24 billion (as of August 25, 2026)
Sector / Industry: Health Care / Pharmaceuticals and Medical Devices
Index membership: Dow Jones Industrial Average, S&P 500
Next earnings date: October 13, 2026
More on Johnson & Johnson stock
Johnson & Johnson relies on a broad healthcare mix rather than a single product line, and that structure shows up in the latest quarter through both pharmaceuticals and devices. The result is a business that can still post 6.6% revenue growth while preserving a dividend of $1.34 per share.
Johnson & Johnson stock at a glance
The stock ended August 25, 2026, at $273.14, with a 52-week range of $173.33 to $276.47 and a market cap of $658.24 billion. That leaves the shares close to their annual high as the market weighs Q2 sales of $25.31 billion against full-year EPS guidance of $11.60 to $11.75.
